News Publication

Information regarding the SKIP-NMD clinical trial of Sarepta’s drug candidate SRP-4053 is now available on www.clinicaltrials.gov.

10 December 2014

Eligibility criteria and other information regarding the clinical trial of Sarepta’s drug candidate SRP-4053, for eligible patients with Duchenne muscular dystrophy is now available on www.clinicaltrials.gov by searching “NCT02310906” in the search box.

Direct link to the posting

The two part study will be conducted at 4 clinical trial sites in the EU, including UK (Newcastle and London),  France (Paris), and Italy (Rome). 

Patients may contact a clinical trial site for more information and may also contact trialinfo@sarepta.com